CEO Greg Collier appointed Director of POH

Hi all,
Yesterday our CEO was appointed as one of 3 new Directors on the Board of Phosphagenics (ASX POH).
I know they sometimes spread themselves across a few Boards and must have applied for the position but believe we're paying him well and when our trial results come out would like to know that he intends to focus 100% on IVX.
Possibly he has done this because of some strategic value to both companies or maybe because he can see benefit in the other 2 Appointees knowledge - here is some background on the other two he will be rubbing shoulders with:

Mr Peter Lankau served as the Chief Executive Officer (CEO) of Endo Pharmaceuticals Inc. from 2005 to 2008 and as Chief Operating Officer from 2003 to 2005. From 2000 to 2003, he served as Senior Vice President of U.S. Business. Endo is a US based Pharmaceutical Company which has over recent years been one of the largest companies commercialising drugs in the pain industry. Endo’s product range includes Lidoderm (lidocaine), Percodan (oxycodone with asprin), Opana (oxymorphone) and Voltaren Gel (diclofenac) licensed from Novartis. In recent years Mr Lankau has served on multiple company boards including Nautilus Neuroscience Inc. which in 2013 sold the assets of that company, including its oral diclofenac product to Depomed Inc. for over $50 million.

Dr Ross Murdoch has over 25 years’ experience in the global Healthcare, Pharmaceutical and Biotech industries and has held senior and executive positions with global Pharmaceutical companies such as GlaxoSmithKline, Astra Zeneca and Shire Pharmaceuticals where he built significant specialised business divisions. He has also worked for much smaller companies such as Prana Biotechnology where he was COO. His appointment to the board was a natural transition, having commenced as CEO of Phosphagenics in January 2015.

Katy